Abstract: SA-PO090

The Influence of Hypophosphatemia on Outcomes during CRRT in AKI Patients

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Jung, Yeonsoon, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Lee, Weon hyung, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Shin, Ho Sik, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Rim, Hark, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Kim, Hyo jong, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Kim, Ye na, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
Background

To assess the role of hypophosphatemia in major clinical outcomes in patients treated with low-or high-intensity continuous renal replacement therapy(CRRT).

Methods

We performed a retrospective analysis of data collected from 620 patients. We divided the patients into two different groups of CRRT intensity (more than or less than 40 mL/kg/hour of effluent generation) and measured serum phosphate level daily.

Results

We obtained a total of 1800 phosphate measurements on days 0,1 and 2 and identified 49 patients (8%), 93 patients (15%), and 142 patients (23%) with hypophosphatemia on each of these respective days. In patients treated with lower-intensity CRRT, 23 episodes of hypophosphatemia/1000 patinet days were identified, compared with 83 episodes/1000 patient days in patients receiving higher-intensity CRRT (P < 0.01). Multiple Cox proportional hazards analyses showed that APACHE score, utilization of vasoactive drugs, and arterial pH on the third CRRT day were significant predictors of mortality; however, serum phosphate level was not a sinificant contributor.

Conclusion

The APACHE score, use of vasoactive drugs, and arterial pH on the 2nd CRRT day were significant predictors of mortality. Hypophosphatemia might not eb a major risk factor of increased motality in patients treate with CRRT.